Formulary Chapter 13: Skin - Full Chapter
|
13.05.02 |
Preparations for psoriasis |
|
|
13.05.02 |
Topical preparations for psoriasis |
|
|
13.05.02 |
Oral retinoids for psoriasis |
|
|
Acitretin (Neotigason®)
|
Formulary
|
For prescribing by dermatologists only in secondary care. NB. Women of child-bearing potential should be on at least one, or preferably two, complementary forms of effective contraception (e.g. barrier and hormonal) for at least 1 month before starting treatment, during treatment, and for at least 3 years after stopping treatment. APCO March 2007.
|
13.05.02.01 |
Topical preparations for the scalp |
|
|
Key |
|
|
Cytotoxic Drug
|
|
Controlled Drug
|
|
High Cost Medicine
|
|
Cancer Drugs Fund
|
|
NHS England |
|
Homecare |
|
CCG |
|
Traffic Light Status Information
Status |
Description |

|
Red: Medicines which should only be prescribed in secondary care by a specialist. |

|
Amber Continuation: Medicines which should be initiated or recommended by a specialist for continuation in primary care. The specialist must notify the GP that the prescribing responsibility has been transferred. |

|
Amber Shared Care Protocol: Medicines which are appropriate to be initiated and stabilised by a specialist, once stabilised the medicine may be appropriate for responsibility to be transferred from secondary to primary care with the agreement of a GP and a formal ‘shared care’ agreement. The shared care protocol must be approved by the Area Prescribing Committee Oxfordshire (APCO). |

|
Green: Medicines which are suitable for initiation and ongoing prescribing within primary care. |

|
Brown: Medicines which should only be prescribed in restricted circumstances. |

|
Black: Medicines which are not recommended for use because of lack of evidence of clinical effectiveness, cost effectiveness or safety. |

|
not used |
|
|